Padeliporfin potassium is under clinical development by Steba Biotech and currently in Phase III for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase III drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Padeliporfin potassium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Padeliporfin potassium overview

Padeliporfin dipotassium (Tookad) is a vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative which acts as an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for treatment of  treatment for other solid tumors. Photodynamic Therapy (PDT) is a non conventional light therapy for treatment of cancer. It uses photosensitive drugs, that are triggered by light from a specific wavelength usually red or infrared on the light spectrum chart. Vascular targeted photodynamic therapy (VTP) with padeliporfin allows tumor-site specific cytotoxicity while

It was also under development for cholangiocarcinoma, choroidal neovascularization, endobronchial cancer, renal cancer, prostate cancer and non-small cell lung cancer.

Steba Biotech overview

Steba Biotech is a biotechnology company that offer research on prostate cancer. It conducts research program in different indicators such as prostate cancer at different stages, oesophagus cancer, upper urinary tract cancer, breast cancer and pancreatic cancer. It offers research and development programs. Steba Biotech research comprises pre clinical, phase 1, phase II, and phase III stages. The company expands its clinical development programs to other indications in oncology in targeting solid tumours in various organs. It has operating offices in France, Israel, USA, Brazil and Switzerland. Steba Biotech is headquartered in Luxembourg City, Luxembourg.

For a complete picture of Padeliporfin potassium’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.